GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » Debt-to-EBITDA

ABL Diagnostics (XPAR:ABLD) Debt-to-EBITDA : -10.77 (As of Jun. 2023)


View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ABL Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. ABL Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €3.02 Mil. ABL Diagnostics's annualized EBITDA for the quarter that ended in Jun. 2023 was €-0.28 Mil. ABL Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -10.77.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ABL Diagnostics's Debt-to-EBITDA or its related term are showing as below:

XPAR:ABLD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.45   Med: -0.01   Max: 6.27
Current: 6.27

During the past 13 years, the highest Debt-to-EBITDA Ratio of ABL Diagnostics was 6.27. The lowest was -1.45. And the median was -0.01.

XPAR:ABLD's Debt-to-EBITDA is ranked worse than
81.78% of 428 companies
in the Healthcare Providers & Services industry
Industry Median: 2.555 vs XPAR:ABLD: 6.27

ABL Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for ABL Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics Debt-to-EBITDA Chart

ABL Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.45 -0.01 - 2.50

ABL Diagnostics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.14 -10.77

Competitive Comparison of ABL Diagnostics's Debt-to-EBITDA

For the Health Information Services subindustry, ABL Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Debt-to-EBITDA falls into.



ABL Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ABL Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 2.656) / 1.064
=2.50

ABL Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 3.015) / -0.28
=-10.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


ABL Diagnostics  (XPAR:ABLD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ABL Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Diagnostics (XPAR:ABLD) Business Description

Traded in Other Exchanges
N/A
Address
72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines